TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03318523
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm
Study: NCT01206530
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dose: 400mg/m2 Route IV infusion over 2 hours Treatment Administration: Day 1
Study: NCT00129467
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects assigned to placebo will receive 1 capsule of placebo twice per day (bid) for 3 days and then 2 capsules bid for the remainder of the study. Should a subject have a 50% decrease in their depressive symptoms as measured by the Montgomery Asberg Depression Rating Scale (MADRS) at the initial dose of placebo, they will be maintained at that lower dose as long as their MADRS score remains reduced by 50%.~If subjects have side effects when increasing the dose to 2 capsules bid, they will drop back to 1 capsule bid. If the participant develops psychosis or cardiac events, they will be discontinued from the intervention.
Study: NCT00189501
Drug: Sensipar®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01026220
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01026220
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02027753
Drug: Sulphonylurea
Normalized name: metformin and sulfonylureas
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: tablet Route of administration: oral
Study: NCT01573156
Drug: Light activated WST11
Approvals — FDA: no, EMA: no, PMDA: no
Description: WST11-mediated VTP will consist of the combination of a single IV administration of WST11 at doses of 2 mg/kg, or 4mg/kg using 753 nm laser light at a fixed power (150 mW/cm) and energy (200 J/cm) delivered through percutaneous optical fibres. The fibres are introduced into transparent needles that are positioned in the areas of interest under CT image guidance. After a minimum of 3 patients at each drug dosage (2 \& 4 mg/kg) has been treated with a light energy of 200 J/cm, the general and local safety will be assessed. The safety results of the first 3 patients treated in each drug dose/number of fibres combination will be reviewed by the investigators prior to escalation to a higher drug dose/number of fibres combination.
Study: NCT01009086
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC injections
Study: NCT00003552
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01496755
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single/multiple doses
Study: NCT01496755
Drug: RG7667
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single/multiple ascending doses
Study: NCT02193113
Drug: KVD001 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: A novel plasma kallikrein inhibitor
Study: NCT01229449
Drug: Ibuprofen/acetaminophen
Normalized name: ibuprofen/acetaminophen 125 mg-250 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet of ibuprofen 200 mg plus acetaminophen 500 mg and one placebo tablet, single dose taken orally with 300 ml water
Study: NCT01229449
Drug: Ibuprofen/acetaminophen (higher dose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two tablets of ibuprofen 200 mg plus acetaminophen 500 mg, single dose taken orally with 300 ml water
Study: NCT01229449
Drug: Nurofen Plus®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two tablets ibuprofen 200mg plus codeine 12.8mg (Nurofen Plus®), single dose taken orally with 300 ml water
Study: NCT01229449
Drug: Panadeine® Extra
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two tablets acetaminophen 500 mg plus codeine 15 mg (Panadeine® Extra), single dose taken orally with 300 ml water
Study: NCT01229449
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two placebo tablets, single dose taken orally with 300 ml water
Study: NCT04117698
Drug: Antitubercular treatment (RIFATER ©)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of ocular inflammation by antitubercular treatment  add-on of local corticosteroid therapy comprising:~* RIFATER © (Isoniazid + Rifampicin + Pyrazinamide) + Ethambutol (13.5-20 mg / kg / day) for 2 months then RIFINAH © (Isoniazid + Rifampicin) for 4 months~* associated with a treatment similar to the control group.
Study: NCT04117698
Drug: RIFINAH ©
Approvals — FDA: no, EMA: no, PMDA: no
Description: RIFINAH ©
Study: NCT01789606
Drug: Ibuprofen 600 mg Immediate Release/Extended Release Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 600 mg Immediate Release/Extended Release Caplet to be adminstered orally (i.e., one caplet every 12 hours, not to exceed 2 caplets per day) for pain.
Study: NCT03230682
Drug: antidepressant
Normalized name: Antidepressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: regular one-drups treatment of selective serotonin reuptake inhibitor(SSRIs)
Study: NCT02128074
Drug: KRX-0502
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1g tablets of KRX-0502
Study: NCT01204762
Drug: pegIFN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Syringe, Subcutaneous, 180 μg, Once Weekly, 48 weeks
Study: NCT01204762
Drug: pegIFNα-2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Syringe, Subcutaneous 180 μg, Once Weekly, 48 Weeks
Study: NCT03574402
Drug: AZD3759
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg PO BID on days 1-28. 28 days as one cycle.
Study: NCT02264028
Drug: [14C]-DK-AH 269 CL, solution for infusion
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02264028
Drug: [14C]-DK-AH 269 CL, drinking solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02169856
Drug: Drug: Inj. Ketorolac 30 mg IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 doses for analgesia. 1st immediate postoperative, 2nd at 8 hours postoperative and 3 rd at 16 hours postoperative period
Study: NCT02169856
Drug: Inj. Zantac 50mg IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses. 1st at immediate postoperative and 2nd 12 hours after surgery
Study: NCT00293020
Drug: BEMA Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: buccal soluble film; 200, 400, 600, 800, 1200 mcg fentanyl; up to 4 times daily
Study: NCT01147848
Drug: Placebo (1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation powder inhaled orally once daily for 24 weeks
Study: NCT01147848
Drug: Placebo (2)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation powder inhaled orally twice daily for 24 weeks
Study: NCT00685737
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule
Study: NCT03783182
Drug: 10% glucose solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose solution that can be used for injection, but in this case it is used perorally (one ml)
Study: NCT04506034
Drug: IV saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: received i.v. saline infusion.
Study: NCT02267681
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl for sedation/analgesia
Study: NCT03713957
Drug: GRF6021
Approvals — FDA: no, EMA: no, PMDA: no
Description: GRF6021 for IV infusion
Study: NCT05865431
Drug: Zinc Oxide and Avobenzone
Normalized name: Zinc Oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zinc Oxide is applied to one area of the forearm, Avobenzone is applied to another area of the forearm.
Study: NCT01554995
Drug: LCB01-0371
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCB01-0371 50mg (Cohort 1) 100mg (Cohort 2) 200mg (Cohort 3) 400mg (Cohort 4) 600mg (Cohort 5)
Study: NCT03549715
Drug: MVAC Protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Methotrexate 30 mg/m2 IV D1~2. Vinblastine 3 mg/m2 IV D1~3. Adriamycin (doxorubicin) 30 mg/m2 IV D1~4. Cisplatin 70 mg/m2 IV D1
Study: NCT04650555
Drug: BIO 300 Oral Powder
Normalized name: Bio-Kool
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amorphous solid dispersion of genistein milled into a powder
Study: NCT00220298
Drug: Testosterone undecanoate (TU) - NebidoTM
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug treatment with 14 injections of one ampoule of Nebido (1000 mg of testosterone undecanoate) at individually adjusted injection intervals
Study: NCT02248298
Drug: 3h-AFL-PDT
Normalized name: (1,2,6,7-3H)-testosterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at 300-550µm ablation depth, level 1 coagulation, 22% treatment density, and a single pulse. In the 3h-MAL-PDT group, the above mentioned procedures were not performed. Immediately after AFL treatment, an approximately 1-mm thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, St. Paul, MN, USA). After incubation for 3 hours, the dressing and cream were removed, and the area was cleansed with saline. The area was irradiated with a red light-emitting diode lamp (Aktilite CL 128; PhotoCure ASA, Oslo, Norway) with peak emission at 632 nm, placed 5 cm away from the skin surface and total light dose of 37 J/cm-2
Study: NCT02248298
Drug: 3hr-MAL-PDT
Normalized name: maleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: an approximately 1-mm thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, St. Paul, MN, USA). After incubation for 3 hours, the dressing and cream were removed, and the area was cleansed with saline. The area was irradiated with a red light-emitting diode lamp (Aktilite CL 128; PhotoCure ASA, Oslo, Norway) with peak emission at 632 nm, placed 5 cm away from the skin surface and total light dose of 37 J/cm-2.
Study: NCT01978613
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets for one-daily oral administration.
Study: NCT01881126
Drug: travatan 0.004%
Normalized name: Travatan 0.004% Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Travatan 0.004% administered to both eyes once daily for 12 weeks.
Study: NCT01791933
Drug: herbal medicine
Normalized name: Herbal medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120ml of Chuna herbal medicine(Ostericum koreanum, Eucommia ulmoides, Acanthopanax Sessiliflorus, Achyranthes bidentata, Psoralea corylifolia, Peucedanum japonicum, Cibotium barometz, Lycium chinense, Boschniakia rossica, and Cuscuta chinensis) taken twice a day 30 minutes after meals for more than 2 months
Study: NCT03536806
Drug: Saline 0.9%
Normalized name: CVS Saline 0.9% Nasal Mist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients assigned to control group will be administered saline 0.9% in bolus of 10 cm3 within 2-3 minutes. BP will be measured before injection.
Study: NCT02471196
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice a day
Study: NCT03334435
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT03273634
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02291731
Drug: Continuous use of topical autologous serum
Normalized name: Ivy Dry Super Continuous Spray Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicone-hydrogel SCLs combined with 20% (v/v) autologous serum eye drops were used until complete re-epithelialization. SCLs were removed after total re-epithelialization and patients were subsequently randomized divided into two groups: (1) with and (2) without continuous use of topical autologous serum for an additional 2 weeks after SCLs removal.
Study: NCT00599612
Drug: GW856553
Approvals — FDA: no, EMA: no, PMDA: no
Description: A dose of 10mg GW856553 containing 50µCi of \[14C\]GW856553 will be delivered as 100mL of a 0.1mg/mL GW856553/0.5 µCi/mL oral solution.
Study: NCT02185196
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20,000 IU Miglyol-oil in children \<6 months, 50,000 IU in children 6-12 months and 1,00,000 IU in children 13-59 months of age on first day and thereafter 10,000 IU for next 4 days
Study: NCT02251093
Drug: Lcr Regenerans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage: 1 vaginal capsule per day Route of administration: intravaginal Treatment duration: One 21-day cycle
Study: NCT01439373
Drug: GSK2336805
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Investigational Drug
Study: NCT01439373
Drug: GSK2336805 Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of Investigational Drug
Study: NCT01011829
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo dose will start at 0.5 mg (sugar pill) daily for days 1-3, followed by 0.5 mg twice daily for days 4-7, followed by 1 mg twice daily from day 8 until completion of the medication period (end of week 8).
Study: NCT02708355
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules
Study: NCT01959243
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ophthalmic solution to be applied as directed.
Study: NCT03549650
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be randomly assigned to receive Placebo oral capsule TID for 6 weeks.~For blinded distribution, each bottle of medications will be labeled with a random number for identification.~The study participants will be monitored every 2 weeks with phone calls from the study team to evaluate their condition and decide if the medication is tolerated and whether it should be continued or stopped.
Study: NCT03372200
Drug: FYU-981
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral daily dosing for 14 weeks
Study: NCT00334711
Drug: Sulfonylurea
Normalized name: Sulfonylurea
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01792401
Drug: Probiotics
Normalized name: probiotics
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01792401
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01429480
Drug: Patient controlled analgesia
Normalized name: PATIENT CONTROLLED ANALGESIA VIAL
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00796302
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One pill will be taken once daily for the first 4 days and then twice daily until Week 21.
Study: NCT01078168
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00812565
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercially available 0.9% isotonic sodium chloride solution.
Study: NCT04591847
Drug: Placebo drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo drugs 1 tab oral weekly
Study: NCT03281083
Drug: Levothyroxine Sodium
Normalized name: Levothyroxine Sodium
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01748825
Drug: MK-1775 (AZD1775)
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-1775 (AZD1775) is an inhibitor of Wee1-kinase.In preclinical models, MK-1775 selectively enhanced chemotherapy-induced death of cells deficient in tumor protein p53 (p53) signaling.
Study: NCT04487652
Drug: with CoQ10 spray application
Approvals — FDA: no, EMA: no, PMDA: no
Description: After surgical recession coverage a CoQ10 spray will be applied during the early phase of wound healing.
Study: NCT04487652
Drug: with placebo spray application
Approvals — FDA: no, EMA: no, PMDA: no
Description: After surgical recession coverage a placebo spray will be applied during the early phase of wound healing.
Study: NCT01624675
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive placebo matching with risperidone orally up to 8 weeks.
Study: NCT03311373
Drug: Regimen B
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 inhalations BGF MDI; AeroChamber Plus Flow-Vu spacer device; no oral charcoal - test formulation/total systemic exposure
Study: NCT03311373
Drug: Regimen D
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 inhalations BGF MDI; AeroChamber Plus Flow-Vu spacer device; with oral charcoal - test formulation/lung exposure
Study: NCT04594928
Drug: GLPG3667
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLPG3667 capsules
Study: NCT00003214
Drug: in vitro sensitivity-directed chemotherapy
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04594928
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules
Study: NCT02301624
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of matching placebo. Participants received placebo only during the Blind Induction Phase.
Study: NCT00895310
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone is taken by mouth 20 mg every morning and 10 mg every evening.
Study: NCT02772627
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets; oral route.
Study: NCT04322682
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive the placebo 0.5 mg per os (PO) twice daily for the first 3 days and then once daily for the last 27 days. If a dose is missed, it should not be replaced.
Study: NCT00605280
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinicians decision to use optional laser therapy.
Study: NCT01775904
Drug: LY2886721 in a Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT00619307
Drug: Rebif New Formulation + prophylactic Ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects, currently on Rebif® 44 mcg three times a week, using Rebiject II as an injection device and having received Rebif® full dose 44 mcg three times a week for at least 6 months, receives systematically 400 mg ibuprofen as prophylactic treatment against flu-like symptoms on days when Rebif New Formulation 44 mcg three times a week is injected
Study: NCT01662310
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants who transitioned from run-in or stabilization phase will receive matching placebo to paliperidone ER once daily during DB phase of the study.
Study: NCT02446301
Drug: Bain®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine HCl 20mg, IM injection
Study: NCT02446301
Drug: SDE
Normalized name: Spasdel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sebacoyl Dinalbuphine Ester 150mg/2ml, IM injection
Study: NCT01826474
Drug: PRO045, 3.0 mg/kg/week
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection
Study: NCT01826474
Drug: PRO045, 6.0 mg/kg/week
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection
Study: NCT01826474
Drug: PRO045, 9.0 mg/kg/week
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection
Study: NCT01826474
Drug: PRO045, selected dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection
Study: NCT00884221
Drug: Highly purified menotrophin
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: The gonadotrophin starting dose was 150 IU daily for the first 5 days. From stimulation day 6 and onwards, dosing could be adjusted according to individual participant response. The dose adjustment could be by 75 IU per adjustment and could not be done more frequently than every 4 days. The maximum allowed gonadotrophin dose was 375 IU daily and participants could be treated with gonadotrophin for a maximum of 20 days.~NOTE: The gonadotrophins (highly purified menotrophin and the active comparator recombinant FSH) were administered in an identical fashion.
Study: NCT00619307
Drug: Rebif New Formulation + ibuprofen PRN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects, currently on Rebif® 44 mcg three times a week, using Rebiject II as an injection device and having received Rebif® full dose 44 mcg three times a week for at least 6 months, should not administer Ibuprofen before the first Rebif New Formulation injection. If flu-like symptoms occur after the 44 mcg Rebif New Formulation injection then the subject can administer 400 mg ibuprofen. This should only be administered after the Rebif New Formulation injection and not before the Rebif New Formulation injection.
Study: NCT00913926
Drug: E2/LNG oral (Wellnara, BAY86-5029)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in daily life treatment receiving Wellnara according to local drug information.
Study: NCT00711789
Drug: Saline placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline placebo will be given by continuous infusion according to a blood-pressure base protocol. This protocol will also incorporate noradrenaline for blood pressure control (as is true in the active drug arm), such that blood pressure targets will be rapidly achieved in both arms of the study; the only difference being that in the active drug arm, at least part of the pressor effect will be provided by angiotensin II.
Study: NCT00020878
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosing will occur for a total of 6 months. 400 mg by mouth twice daily.
Study: NCT01880723
Drug: Placebo saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: nebulized 3mL normal saline) using a Power Neb2 nebulizer
Study: NCT03720288
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient will follow the treatment according to inclusion sequence, receiving the corresponding number medication.
Study: NCT01320592
Drug: PD0332991
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03408184
Drug: Lumbar paravertebral group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: A mixture of 0.5 ml /kg bupivacaine (0.25%), and 0.5µg/Kg dexmedetomidine and Epinephrine 5 microgram/ ml.
Study: NCT02429791
Drug: DTG 50 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received one oral tablet of 50 mg DTG daily administered concomitantly with RPV. Each DTG tablet contained 52.62 mg dolutegravir sodium salt, which was equivalent to 50 mg dolutegravir free acid.
Study: NCT02429791
Drug: RPV 25 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received one oral tablet of 25 mg RPV daily administered concomitantly with DTG along with a meal. Each RPV tablet contained 27.5 mg of rilpivirine hydrochloride, which was equivalent to 25 mg of RPV.
Study: NCT03376659
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000mg orally twice a day, Monday - Friday Weekly